I. O. Belogortsev
A5093771773- Cancer Immunotherapy and Biomarkers
- Endometrial and Cervical Cancer Treatments
- Genetic factors in colorectal cancer
- Endometriosis Research and Treatment
- Melanoma and MAPK Pathways
- CAR-T cell therapy research
State Healthcare Institution "Regional Clinical Oncological Dispensary"
2024
Abstract Background: BCD-217-2/OCTAVA (NCT05732805) is an international, multi-center, randomized, double-blind, placebo-controlled phase III study conducted to access the efficacy and safety of prolgolimab+nurulimab (BCD-217) combination therapy with continued prolgolimab compared monotherapy as 1st line treatment for patients (pts) unresectable or metastatic melanoma (un/mM). BCD-217 a fixed-dose nurulimab (aCTLA-4, 5 mg/ml) (aPD-1, 15 was recently approved un/mM in Russia. Here we present...
Aim . To assess the efficacy and safety of lenvatinib pembrolizumab for treatment mismatch repair-proficient endometrial cancer (EC) in routine clinical practice Russia. Materials methods This multicenter, retrospective, cohort study included patients with recurrent metastatic EC from 37 centers Russia treated between May 2020 April 2023. Patients histologically verified without microsatellite instability who received ≥1 course pembrolizumab/lenvatinib therapy were study. The primary...
Prolgolimab is the first Russian PD-1 inhibitor approved for first-line treatment of unresectable or metastatic melanoma and advanced non-small cell lung cancer. It was in two weight-based regimens 1 mg/kg Q2W 3 Q3W, but because re-evaluation dosing paradigm, studying a fixed-dose regimen considered perspective.
Background. Endometrial cancer (EC) treatment outcomes need to be improved. Immunotargeted therapy lead long-term and delayed effects compared chemotherapy. Estimation of efficacy quality life are crucial when we talking about in whole. Aim. To evaluate the clinical lenvatinib plus pembrolizumab patients with EC. Materials methods . The study included 43 stages I-IV EC mismatch repair-proficient tumors duration more than 9 months. We evaluated median progression-free survival, objective...